Staging glaucoma patient: why and how?
Remo Susanna, Roberto M Vessani
https://pubmed.ncbi.nlm.nih.gov/19834563Actively Recruiting
Phase Not Applicable
Age: 18Years +
All Genders
ID07147647
Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Intraocular Pressure in Non-Caucasian Open Angle Glaucoma Patients
Led by Select Eye Care · Updated on 2025-08-29
60
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating how well Direct Selective Laser Trabeculoplasty (DSLT) lowers eye pressure in adult non-Caucasian patients with primary open angle glaucoma (POAG). The study focuses on comparing eye pressure without glaucoma medications (washed out eye pressure) before and 6 months after the DSLT procedure. This research aims to better understand the effectiveness of DSLT in lowering intraocular pressure in this patient group. Participants will receive the DSLT treatment using the Belkin Vision Eagle Device on one or both eyes. The study includes follow-up visits at 1 month, 3 months, and 6 months after the procedure to monitor vision and eye pressure. These visits assess the reduction in eye pressure and whether participants need additional glaucoma medications or procedures during the 6 months after treatment. During the study, participants will have their vision and intraocular pressure measured at scheduled visits. Researchers will track the amount of eye pressure reduction, the proportion of eyes achieving significant pressure decrease, and the number of medication-free eyes at 6 months. Safety and the need for any extra glaucoma treatments will also be monitored. The total study duration for each participant is 6 months after the DSLT procedure.
CONDITIONS
Brief Title
Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Adult patients of Black African descent scheduled to undergo DSLT treatment in one or both eyes.
- Diagnosis of mild to moderate primary open angle glaucoma (POAG).
- Mild to moderate POAG defined as Stage 2 or better of the Hodapp-Anderson-Parrish glaucoma staging system.
- Treatment naive or washed out intraocular pressure (IOP) at time 0 ranging from 61 21 through 32 mm Hg.
You will not qualify if you...
- Patients on IOP-lowering medications who did not successfully complete medication washout at the time of the procedure.
- Patients who have had prior glaucoma-related surgeries or procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).
- Patients with secondary glaucoma such as angle-closure glaucoma, neovascular glaucoma, or glaucoma from trauma or systemic diseases.
- Patients with significant ocular conditions including advanced cataracts, retinal diseases, or any condition complicating IOP or vision assessment.
- Subjects who are pregnant, breastfeeding, or intend to become pregnant during the study period.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Implementation
Duration - 1 day
Participants receive Direct Selective Laser Trabeculoplasty (DSLT) treatment using the Belkin Vision Eagle Device.
1 visit (in-person)
Post-operative Follow-up
Duration - 6 months
Participants are monitored for intraocular pressure reduction and need for secondary interventions after DSLT treatment.
Follow-up visits at 1 month, 3 months, and 6 months post-DSLT
Trial Site Locations
Total: 1 location
1
Select Eye Care
Elkridge, Maryland, United States, 21075
Actively Recruiting
Loading map...
Research Team
S
Scott E LaBorwit, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease.
Richard P Mills, Donald L Budenz, Paul P Lee...
https://pubmed.ncbi.nlm.nih.gov/16386972A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
Bret A Hughes, Jason Bacharach, E Randy Craven...
https://pubmed.ncbi.nlm.nih.gov/16148589Primary open-angle glaucoma in blacks: a review.
Lyne Racette, M Roy Wilson, Linda M Zangwill...
https://pubmed.ncbi.nlm.nih.gov/12745004The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.
Michael A Kass, Dale K Heuer, Eve J Higginbotham...
https://pubmed.ncbi.nlm.nih.gov/12049574Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: Six-Year Results of Primary Selective Laser Trabeculoplasty versus Eye Drops for the Treatment of Glaucoma and Ocular Hypertension.
Gus Gazzard, Evgenia Konstantakopoulou, David Garway-Heath...
https://pubmed.ncbi.nlm.nih.gov/36122660Direct selective laser trabeculoplasty in open angle glaucoma study design: a multicentre, randomised, controlled, investigator-masked trial (GLAUrious).
Nathan Congdon, Augusto Azuara-Blanco, Yoram Solberg...
https://pubmed.ncbi.nlm.nih.gov/34433548Automated Direct Selective Laser Trabeculoplasty: First Prospective Clinical Trial.
Mordechai Goldenfeld, Michael Belkin, Masha Dobkin-Bekman...
https://pubmed.ncbi.nlm.nih.gov/34003939